Rexulti 1mg Dose Duration
Patients should remain on Rexulti 1 mg for approximately 1 week before dose escalation, as this represents the standard titration schedule established in clinical trials.
Dosing Algorithm Based on Indication
For Schizophrenia (Adults)
The FDA-approved titration schedule is clearly defined 1:
- Days 1-4: Start at 1 mg once daily
- Days 5-7: Continue 1 mg once daily
- Day 8 onwards: Increase to target dose of 2-4 mg once daily
This means the 1 mg dose duration is exactly 7 days before escalation to the therapeutic range of 2-4 mg daily. The clinical trials (Studies 3 and 4) demonstrated that 2 mg and 4 mg doses were superior to placebo, while 1 mg is purely a titration dose 1.
For Adjunctive Treatment of Major Depressive Disorder
The titration follows a similar but slightly different pattern 1:
- Week 1: 0.5 mg once daily
- Week 2: 1 mg once daily
- Week 3 onwards: Increase to 2-3 mg once daily (target dose)
For MDD, patients remain on 1 mg for approximately 1 week (Week 2 of treatment) before escalating to the therapeutic dose of 2-3 mg.
For Agitation in Alzheimer's Dementia
The dosing varies by study protocol 1:
- Start at 0.25-0.5 mg once daily
- Gradual escalation over 2-4 weeks
- Target dose: 2-3 mg once daily
Critical Clinical Considerations
The 1 mg dose should not be considered therapeutic for any indication. It serves solely as a titration step to minimize adverse effects, particularly:
- Akathisia (most common dose-limiting side effect)
- Somnolence
- Weight gain
- Gastrointestinal effects
Response Timeline Expectations
Do not expect clinical response at 1 mg. Based on clinical trial data:
- Schizophrenia: Separation from placebo begins around Week 2-3 at therapeutic doses (2-4 mg) 1
- MDD (adjunctive): Response typically observed by Week 6 at doses of 2-3 mg 1, 2
- Agitation in AD: May require 6-12 weeks at therapeutic doses (2-3 mg) to demonstrate benefit 3, 4
Common Pitfall to Avoid
Do not maintain patients on 1 mg expecting therapeutic benefit. The evidence consistently shows that 1 mg is subtherapeutic across all indications. In Study 4 for schizophrenia, the 2 mg dose showed marginal efficacy (not statistically significant), while 4 mg demonstrated clear superiority to placebo 1. For MDD, doses ≤2 mg showed better risk/benefit balance than higher doses, but 1 mg alone was not studied as a maintenance dose 2.
Dose Escalation Decision Points
After 1 week at 1 mg:
- Assess tolerability (akathisia, sedation, orthostasis)
- If well-tolerated: Escalate to 2 mg (minimum therapeutic dose)
- If poorly tolerated: Consider alternative antipsychotic or slower titration (though not standard)
- Target maintenance dose: 2-4 mg for schizophrenia; 2-3 mg for MDD; 2-3 mg for agitation in AD
The evidence is unequivocal that 1 mg is a brief transitional dose, not a therapeutic endpoint.